Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)

Trial Profile

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2017

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2017 Results assessing immunological profile changes of secondary progressive multiple sclerosis (SPMS) patients after BAF312 treatment, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 16 Feb 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top